CatalystFDA/Bio

BEAM DROPS AFTER UPDATING PHASE 1/2 TRIAL DATA FOR GENE-EDITING DRUG - SEEKINGALPHA

Phase 1/2 trial data update triggered sharp selloff in gene-editing drug developer.

What changed

Phase 1/2 trial data update triggered sharp selloff in gene-editing drug developer.

Why it matters

Phase 1/2 trial data update triggered sharp selloff in gene-editing drug developer. — impact context not separately stored; see What changed.

Sources